The Evolving Landscape of First-Line Treatment for Urothelial Carcinoma

Speciality: Oncology

Description:

A warm welcome to all the medical professionals in this insightful session presented by Dr. Petros Grivas on "The Evolving Landscape of First-Line Treatment for Urothelial Carcinoma." Historically, platinum-based chemotherapy has been the cornerstone of first-line therapy for locally advanced or metastatic urothelial carcinoma (la/mUC). While effective in some cases, these regimens often come with significant toxicities and a high rate of disease recurrence. This webinar delves into how recent breakthroughs are rapidly transforming this treatment paradigm, offering new hope and improved outcomes for patients.

Dr. Grivas highlights the significant shift from chemotherapy-centric approaches to more targeted and personalized therapies. The success of studies like EV-302, demonstrating the superior efficacy of enfortumab vedotin in combination with pembrolizumab, marks a pivotal moment, establishing a new platinum-free standard of care for la/mUC, even for platinum-tolerant patients. This paradigm shift also includes the role of immune checkpoint inhibitors (ICIs), both as monotherapy for cisplatin-ineligible patients and as switch-maintenance therapy after initial chemotherapy, further extending survival.

Understanding these evolving treatment options is crucial for optimizing patient care. Dr. Grivas's insights emphasize the importance of individualizing treatment decisions based on patient characteristics, biomarker testing, and the latest clinical evidence. This dynamic landscape necessitates continuous learning to integrate novel agents and combination strategies, ultimately leading to better progression-free survival and overall survival for patients with urothelial carcinoma. Stay tuned to Hidoc for more such impactful webinar sessions that keep you at the forefront of medical advancements.

See More Webinars @ Hidoc Webinars